Eye Drops Class Action Lawsuit Filed Over Recalled EzriCare, Delsam Pharma Artificial Tears

Class action lawsuit over recalled eye drops alleges Delsam Pharma and EzriCare Artificial Tears were not adequately treated to prevent bacterial contamination.

  • Recalled Artificial Tears eye drops sold under the EzriCare and Delsam Pharma brands were contaminated with antibiotic-resistant bacteria
  • Infections from the eye drops have already resulted in hospitalizations and at least one death from a blood stream infection
  • Eye drops recall class action lawsuit seeks financial compensation for all consumers
  • Individual eye drops recall settlements are being pursued for individuals with injuries

Following a recall of EzriCare and Delsam Pharma Artificial Tears, which were contaminated with bacteria that has already caused a number of severe infections, hospitalizations and deaths, a class action lawsuit over the eye drugs has been filed on behalf of all consumers who purchased the products.

The complaint (PDF) was filed by Richard Mosely in the U.S. District Court for the Eastern District of Kentucky on February 4, claiming the manufacturers advertised the products as safe for use, while failing to thoroughly test the products for bacterial contamination.

The eye drops class action lawsuit comes as health officials from the U.S. Centers for Disease Control and Prevention (CDC) are continuing to investigate and monitor a growing nationwide outbreak out Pseudomonas aeruginosa infection, which have been linked to bottles of Artificial Tears sold under the brand names EzriCare and Delsam Pharma.

Artificial Tears Eye Drops Recall

The Artificial Tears recall was announced by the U.S. Food and Drug Administration (FDA) on February 2, impacting multiple versions of the lubricant eye drops sold in ½ fluid ounce (15 ml) bottles. The recall included eye drops that were packaged in boxes sold under the brand names EzriCare, as well as Delsam, with the following UPC and NDC codes;

  • Ezricare (blue box): NDC 79503-0101-15 with UPC 3 79503 10115 7, and
  • Delsam Pharma (white box): NDC 72570-121-15 with UPC -72570-0121-15

Officials instructed customers to stop using these products immediately, warning at least 55 individuals had developed Pseudomonas aeruginosa infections after using eye drops between May 17, 2022 and January 19, 2023, with most reporting exposure to the Artificial Tears products.

Of the reported injuries, the FDA has become aware of multiple individuals suffering eye infections after using Artificial Tears that resulted in permanent blindness, while at least one individual died from a severe bloodstream infection.


Did you or a loved one use recalled eye drops?

Lawyers are investigating EzriCare Artificial Tears lawsuits for individuals who experienced eye infections, blindness or other problems following use of the recalled eye drops.


Eye Drops Class Action Lawsuit

According to allegations raised in the eye drops class action lawsuit filed late last week, Mosely raises several allegations against the manufacturers, claiming the companies do not comply with current good manufacturing practice (CGMP) requirements due to their failure to perform appropriate microbial testing. The lawsuit claims the manufacturers are well aware that the eye drops formulation lacked adequate preservatives to remove any chemical used to prevent the growth of bacteria in the eye drops, leaving customers at risk.

Mosely further states the products were inadequately labeled and falsely advertised as safe for their intended purposes and free of bacterial hazards.

As a result of the manufacturer’s negligent misrepresentations and omissions, individuals across the nation have now suffered financial damage by paying a premium for the products, while a growing number of consumers have also suffered vision complications and life threatening infections, according to the complaint.

The lawsuits presents claims of unjust enrichment, negligent misrepresentation/omission and violation of the Kentucky Consumer Protection Act, seeking to represent all similarly situated class members.

Lawyers Are Reviewing Eye Drops Infection Lawsuits Nationwide

As the news about the recent eye drops recall continues to spread, it is expected that the number of Pseudomonas aeruginosa infections from the Artificial Tears could grow significantly in the coming weeks and months.

Lawyers are actively investigating eye drop infection lawsuits against the manufacturers and distributors of EzriCare and Delsam Pharma’s eye drops for multiple injuries and side effects caused by the contamination, including;

  • Eye Infection
  • Partial Blindness
  • Permanent Blindness
  • Bloodstream Infection
  • Other injuries caused by the eye drops
Contact A Lawyer


Settlement benefits may be available for individuals diagnosed with infections or requiring hospital treatment due to problems with the recalled EzriCare Artificial Tears eye drops.



Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.